医学
内科学
曲妥珠单抗
人口
胃肠病学
临床终点
肺癌
临床研究阶段
肿瘤科
癌症
临床试验
外科
乳腺癌
环境卫生
作者
Kōichi Goto,Yasushi Goto,Toshio Kubo,Kiichiro Ninomiya,Sang‐We Kim,David Planchard,Myung‐Ju Ahn,Egbert F. Smit,Adrianus J. de Langen,M. Pérol,Elvire Pons‐Tostivint,Silvia Novello,Hidetoshi Hayashi,Junichi Shimizu,Dong‐Wan Kim,Chih‐Hsi S. Kuo,James Chih‐Hsin Yang,Kaline Pereira,Fu-Chih Cheng,Ayumi Taguchi
摘要
Trastuzumab deruxtecan (T-DXd) 5.4 and 6.4 mg/kg showed robust antitumor activity in multiple cancer indications; however, T-DXd 5.4 mg/kg has not been evaluated in patients with previously treated human epidermal growth factor receptor 2-mutant (
科研通智能强力驱动
Strongly Powered by AbleSci AI
斯寜
YifanWang
827584450
月下独酌42
nenoaowu
典雅问寒
科研小民工
jyy
bc
yang
今天只做一件事
Oracle
maox1aoxin
加菲丰丰
Li
非而者厚
华仔
zho
归尘
Holland
皖公网安备34019202002308
